IMV Inc IMVIF

RE:RE:Anyone hear how the investor presentation went in Boston?

[PoorOpinion]

The other interesting thing at Boston is at around 17min. He talks about IMV having 100% control over the product, Merck/Incyte have no first refusal or anything else with survivac. But then he goes on to say we want to keep that control until at least the end of this year when the data should have rolled in. That would suggest deals might start being made from 2019 onwards. I dont know I've heard that sort of statement before, anybody have any insight on what they've said in the past bout partnering?. For those looking for serious derisking those would certainly provide that, locking-in value. Clearly nothing concrete, no certainty on any timetable on these business developments but would be as serious a development as anything clinical.